Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated Interferon Therapy in CHB Patients After ASO/siRNA Discontinuation
NCT06923280Recruiting
- Sponsor
- Huashan Hospital
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of pegylated interferon alpha in Chronic Hepatitis B (CHB) (2 arms), sponsored by Huashan Hospital. Primary endpoint: HBV DNA and HBsAg undetectable with/without anti-HBs at 72 weeks. Started Aug 2025; status: recruiting.
02
Drugs
pegylated interferon alpha
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06923280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06923280.